Skip to main content

Table 3 The outcomes of critically ill patients with COVID-19 after propensity score matching

From: Dexamethasone versus methylprednisolone for multiple organ dysfunction in COVID-19 critically ill patients: a multicenter propensity score matching study

Outcomes

Number of outcomes/Total number of patients

 

Hazard Ratio (HR) (95%CI)

P-value$

Dexamethasone

Methylprednisolone

P-value

30-day mortality, n (%)

62 (34.8)

25 (41.7)

0.3417^^

0.997 (0.970, 1.025)

0.85

In-hospital mortality, n (%)

64 (35.6)

29 (46.8)

0.1173^^

1.02 (1.0, 1.04)

0.05

    

beta coefficient (Estimates) (95%CI)

P-value$*

MODS at day 3 of ICU admission, Median (Q1,Q3) ∆

5.0 (3.00, 8.00)

6.0 (4.00, 9.00)

0.1151^

0.17 (0.02,0.32)

0.03

VFDs, Median (Q1,Q3)

18.0 (0.00, 27.00)

14.0 (0.00, 27.00)

0.4849^

-0.12 (-0.62,0.39)

0.65

ICU Length of Stay (Days), Median (Q1,Q3)

10.0 (6.00, 18.00)

10.0 (7.00, 18.00)

0.7702^

0.06 (-0.14,0.25)

0.56

Hospital Length of Stay (Days), Median (Q1,Q3)

17.0 (11.00, 26.00)

19.0 (13.00, 27.00)

0.6576^

-0.15 (-0.35,0.05)

0.14

  1. ^Wilcoxon rank sum test is used to calculate the P-value
  2. ^^Chi-square test is used to calculate the P-value
  3. $Time dependent cox proportional hazards regression analysis used to calculate HR and p-value
  4. $*Generalized linear model is used to calculate estimates and p-value